Previous close | 12.22 |
Open | 12.33 |
Bid | 11.21 x 100 |
Ask | 11.31 x 100 |
Day's range | 11.17 - 12.57 |
52-week range | 9.02 - 26.35 |
Volume | |
Avg. volume | 1,134,315 |
Market cap | 543.285M |
Beta (5Y monthly) | 2.52 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.65 |
Earnings date | 08 Aug 2024 - 12 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 34.11 |
Q4 and Full Year 2023 Financial Results Reveal Strategic Advancements in Autoimmune Therapies
– First patient dosed with CABA-201 in the RESET™ (REstoring SElf-Tolerance) clinical trial program – – Initial clinical data from each of the first patients in the RESET-Myositis™ and RESET-SLE™ trials anticipated in 1H24; longer term follow-up on these and additional patients to be reported in 2H24 – – RESET-SSc™ (systemic sclerosis) and RESET-MG™ trials initial clinical data anticipated to be reported in 2H24 – – Rare Pediatric Disease designation granted by FDA for CABA-201 in juvenile derma
PHILADELPHIA, March 20, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, for the treatment of systemic sclerosis (SSc). CABA-201 is in deve